Kequan Fund has led the Series B round for Biomissile Biopharma while HashKey Group is reportedly in “early-stage talks” to raise up to $200 million.
Kequan Fund leads Biomissile’s Series B round
Biomissile Biopharmaceutical, a Suzhou-headquartered biopharmaceutical firm, has secured 200 million yuan ($28.3 million) in a Series B round led by Kequan Fund, set up by Anji Economic Development Zone.
The round, which saw the participation of its previous backer Fosun Health Capital, will support the pre-clinical and clinical research of the firm’s product pipeline, according to a company release on May 18.
Founded in April 2020, the firm discovers and develops multi-specific therapeutic antibodies to treat a wide range of diseases that are currently without effective therapies. Previously, the firm bagged $25 million in a Series A round from Fosun Health Capital in July 2020.
HashKey in ‘early-stage talks’ to raise funds: Report
Hong Kong-headquartered digital asset financial service provider HashKey Group is in the market to raise $100 million to $200 million, Bloomberg reported on May 19.
HashKey, which currently operates one of the only two-licensed crypto exchanges in the city, is reportedly seeking funding at a valuation of over $1 billion.
HashKey’s business spans digital asset exchange, broker platform, custody services, as well as a venture capital fund invested in blockchain companies and projects globally. HashKey Capital, the investment arm of the firm, plans to launch at least two liquid funds to ride on the opportunities in the secondary market, Deng Chao, CEO of HashKey Capital and HashKey Singapore, told DealStreetAsia in an interview earlier.